The Growing Use of Immune Checkpoint Inhibitor-Targeted Therapy Combinations and Challenges in Managing Associated Toxicities

This activity was originally broadcast live as a satellite symposium held in conjunction with HOPA 2022.

Program Description

The scope of immune checkpoint inhibitor (ICI) therapy has expanded with the use of ICI combination strategies, including combining ICIs with molecularly targeted therapies. A growing number of these therapy combinations have been approved by the U.S. Food and Drug Administration for multiple tumor types. Despite the efficacy of these combination therapies, ICIs are associated with a wide spectrum of immune-related adverse effects that may be severe if not appropriately identified and managed. In addition, many of the targeted therapies used in combinations with ICIs have overlapping toxicity profiles. This activity will explore the distinct mechanisms of action and adverse effect profiles of approved and emerging ICIs in combination with oral targeted therapies. Patient cases will be discussed throughout the program to offer pharmacists the opportunity to examine treatment challenges and strategies to manage adverse effects of therapy for patients receiving ICIs/targeted therapy combinations.

Target audience: Oncology pharmacists

Type of activity: Application
Release date: April 29, 2022
Expiration date: April 29, 2023

Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Identify the role of immune checkpoint inhibitor (ICI)-targeted therapy combination regimens in the management of cancer
• Compare adverse effect profiles associated with ICIs and targeted therapies when used alone and in combination with one another
• Investigate strategies to aid in the management of combination drug regimens upon the development of drug-related toxicity

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-22-190-H01-P. The activity is available for CE credit through April 29, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, watch the symposium in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Faculty

Jessica Davis, PharmD, BCOP, CPP, has the following relevant financial relationships with commercial interests to disclose:

Consultant: Sanofi-Genzyme/Regeneron Pharmaceuticals Advisory Board

Speakers Bureau: Exelixis, Inc

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy Seung, PharmD, BCOP, FHOPA; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms